BMF-219 (Figure 5) is a selective and orally bioavailable irreversible inhibitor able to abrogate menin-dependent oncogenic signaling, with antiproliferative effects on menin-dependent AML and diffuse large B-cell lymphoma (DLBCL) cell lines [118]. This evidence concerns the gene MEN1 and diffuse large B-cell lymphoma.